Sarepta : Restructuring and Elenidys - Strategic Plan
4 Articles
4 Articles
Sarepta Axes 500, 36% of Workforce, in Restructuring after DMD Patient Deaths
Sarepta Therapeutics said it will eliminate 36% of its workforce—approximately 500 jobs—in a restructuring that follows the deaths of two Duchenne muscular dystrophy (DMD) patients following treatment with the marketed gene therapy Elevidys® (delandistrogene moxeparvovec-rokl). Under the restructuring, which was announced Wednesday after the close of the markets, Sarepta will pivot much of its research and development toward therapies for five r…
Important Update: Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label
CureDuchenne is sharing a community letter from Sarepta announcing a strategic company restructuring and pipeline prioritization plan. Additionally, Sarepta shared that the U.S. FDA has requested and Sarepta has agreed to include a black box warning in the ELEVIDYS label, resolving any material issues with the ambulant population indication. Sarepta has completed an Expert Committee on a protocol for the use of additional prophylactic immunosupp…
Sarepta: Restructuring and Elenidys – Strategic Plan Sarepta Therapeutics: Restructuring Massive after Deborations in Genic Therapy – Urgent News The pharmaceutical company Sarepta... The post Sarepta: Restructuring and Elenidys – Strategic Plan appeared first on World News.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium